慢性閉塞性肺疾患市場：タイプ別、治療タイプ別、エンドユーザー別、地域別、2026～2032年

慢性閉塞性肺疾患市場の評価-2026～2032年

COPDの罹患率が世界中で上昇し、慢性閉塞性肺疾患の普及を促進しています。若者の間でタバコの消費量が増加し、ジェネリック医薬品の使用に対する一般市民の意識が高まっているため、市場規模は2024年に211億7,000万米ドルを突破し、2032年には約353億米ドルの評価額に達する見込みです。

これに加えて、新興国ではヘルスケアへの支出が増加しており、慢性閉塞性肺疾患の治療に拍車がかかっています。政府や大手企業による研究開発投資の拡大が、2026～2032年のCAGR 7.28%での市場成長を可能にしています。

慢性閉塞性肺疾患市場定義/概要

慢性閉塞性肺疾患（COPD）は、肺気腫や慢性気管支炎としても知られ、気流制限や呼吸障害を引き起こす肺疾患です。症状には、咳、呼吸困難、喘鳴、疲労感などがあります。一般的な原因には喫煙や大気汚染があり、COPD患者は他の健康問題のリスクが高いです。慢性気管支炎は気管支に炎症を起こし、腫れや粘液の蓄積を引き起こし、気管支の開口部を狭くして肺への空気の出入りを困難にします。肺気腫は肺の底にある気嚢（肺胞）が破壊されたもので、気管を幹、気管支を枝、気嚢を葉に見立てた逆さまの木のようなものです。

慢性閉塞性肺疾患（COPD）の治療は、症状を緩和し、生活の質を改善し、病気の進行を遅らせることに重点を置いています。気道の筋肉を弛緩させ気流を改善する気管支拡大薬、炎症を抑える吸入コルチコステロイド、効果を高める吸入薬の併用などが主要内容です。運動訓練、栄養アドバイス、教育を含む肺リハビリテーションプログラムは、患者のエンパワーメントと機能改善のために極めて重要です。重症例では酸素補充療法が必要な場合もあります。さらに、病気の進行を止めるためには禁煙が不可欠であり、ワクチン接種と定期的なモニタリングは増悪の予防と併存疾患の効果的な管理に役立ちます。

COPD治療の将来は、個別化医療、先進ドラッグデリバリーシステム、革新的な治療法に焦点が当てられると考えられます。主要動向としては、特定の炎症経路を標的とした生物製剤、肺組織修復のための遺伝子治療や再生医療、遠隔医療や遠隔モニタリングなどのデジタルヘルス技術、新しい吸入器技術や薬剤製剤などが挙げられます。これらの進歩は、COPD患者の転帰と生活の質を改善し、患者管理と治療計画の遵守を強化することを目的としています。

慢性閉塞性肺疾患（COPD）に対する意識の高まりは、慢性閉塞性肺疾患の採用をどのように増加させるか？

慢性閉塞性肺疾患（COPD）に対する認識が高まり、それに伴い診断や認知度も世界的に向上しています。ヘルスケア専門家や一般市民の間でこのような認識が高まることは、COPDを早期に発見し、タイムリーな介入とより良い管理戦略を可能にする上で極めて重要です。その結果、診断ツールの改善、より効果的な治療、COPDの理解と対策に向けた研究への需要が高まっています。このような状況の変化は、COPDが個人や医療システムに与える影響を軽減するための教育や積極的なヘルスケアイニシアチブの重要性を強調し、市場の成長を後押ししています。

世界のCOPD患者の増加は、公衆衛生上の重大な課題であり、その一因は、依然としてCOPDの主要な危険因子であるタバコの喫煙です。成人の喫煙率が世界的に上昇していることがCOPDの負担増につながっており、包括的な禁煙プログラムとタバコ規制の強化が急務であることを浮き彫りにしています。さらに、汚染物質への職業暴露や室内空気汚染はCOPD発症リスクをさらに悪化させています。規制施策や職場介入を通じてこれらの環境要因に対処することは、COPDの発症と進行を抑制し、それによって罹患者のQOLを向上させ、ヘルスケア資源への負担を軽減する上で極めて重要です。

スパイロメトリー、CTスキャン、バイオマーカー検査などの診断技術の進歩により、慢性閉塞性肺疾患（COPD）の管理は大幅に改善されました。これらの技術により、早期発見、個別化された治療計画、症状コントロールの改善が可能になりました。さらに、気管支拡大薬、コルチコステロイド、生物製剤などの治療オプションは、COPD患者の生活の質を向上させています。例えば、2021年2月、SanofiとRegeneron Pharmaceuticalsは、元喫煙者のCOPD急性増悪を抑制するイテペキマブの有効性と安全性を評価する第III相臨床検査を実施しており、検査終了は2024年7月に予定されています。

慢性閉塞性肺疾患（COPD）の治療に使用される薬剤の副作用の増加は、その適用を抑制するか？

慢性閉塞性肺疾患（COPD）の治療に使用される薬剤の副作用の増加は、市場の成長を著しく阻害します。National Center for BIoTechnology Informationによると、吸入ステロイドなどの薬剤は口腔感染症、あざ、嗄声を引き起こす可能性があり、患者のコンプライアンスを阻害し、市場拡大を制限します。さらに、これらの薬剤を使用しているCOPD患者は、インフルエンザ、風邪、肺炎などの呼吸器感染症にかかりやすく、治療をさらに複雑にし、ヘルスケアコストを増加させます。

さらに、COPDの複雑さと治療に対する患者の反応のばらつきが、薬剤開発を特に困難にしています。第II相検査であるTERRANOVA検査やGALATHEA検査のような臨床検査では、有効性や安全性を実証するのに苦労することが多く、COPD市場の進展をさらに妨げています。このような医薬品開発の不確実性は、投資を抑制し、新しい治療法の導入を遅らせる。

COPDの新薬開発には、臨床検査での高い失敗率など課題が山積しています。例えば、2019年5月、喘息治療であるベンラリズマブは、中等症から超重症のCOPD患者の年間COPD増悪率を減少させることができなかりました。このような挫折は、効果的な治療法を発見することの難しさを浮き彫りにし、市場の成長展望を制限しています。

うつ病、心臓病、肺動脈の高血圧、肺がんなど、COPDに伴う合併症もまた、効果的な管理と市場成長の課題となっています。これらの合併症の重症度は包括的な治療アプローチを必要とするが、費用と資源がかかることが多く、市場の成長を抑制しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 慢性閉塞性肺疾患市場：タイプ別

• 慢性気管支炎
• 肺気腫

第5章 慢性閉塞性肺疾患市場：治療タイプ別

• 薬剤
• 気管支拡大薬単剤療法
• 短時間作用型β2-アゴニスト（SABAS）
• 長時間作用性β2-アゴニスト（LABAS）
• 抗コリン薬
• 抗炎症薬
• 経口と吸入コルチコステロイド
• 抗ロイコトリエン薬
• 外科手術
• 肺容量減少手術（LVRS）
• 肺移植、バルレクトミー
• その他
• 酸素療法

第6章 慢性閉塞性肺疾患市場：エンドユーザー別

• 病院
• 在宅医療
• クリニック
• その他

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline（GSK）
• Novartis
• Merck & Co.
• Pfizer
• Teva Pharmaceuticals
• Sanofi
• Mylan
• Chiesi Farmaceutici
• Sunovion Pharmaceuticals
• Orion Corporation
• Cipla
• Reddy's Laboratories
• Vectura Group
• Circassia Pharmaceuticals
• Theravance Biopharma
• Verona Pharma
• Glenmark Pharmaceuticals
• Pulmatrix

第11章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 供給源と参考文献

Chronic Obstructive Pulmonary Disease Market Valuation - 2026-2032

Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2032.

In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2026 to 2032.

Chronic Obstructive Pulmonary Disease Market: Definition/ Overview

Chronic obstructive pulmonary disease (COPD), also known as emphysema or chronic bronchitis, is a lung disease causing restricted airflow and breathing issues. Symptoms include cough, difficulty breathing, wheezing, and tiredness. Common causes include smoking and air pollution, and those with COPD are at higher risk of other health issues. Chronic bronchitis causes inflammation of the bronchial tubes, causing swelling and the buildup of mucus, which narrows the tube's opening, making it difficult for air to enter and exit the lungs. Emphysema is the breakdown of air sacs (alveoli) at the bottom of the lung, similar to an upside-down tree with the windpipe as the trunk, bronchi as branches, and air sacs as leaves.

Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.

The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.

How will Rising Awareness of Chronic Obstructive Pulmonary Disease (COPD) Increase Adoption of Chronic Obstructive Pulmonary Disease?

Rising awareness of chronic obstructive pulmonary disease (COPD) continue to advance, there is a corresponding increase in the diagnosis and recognition of the condition globally. This heightened awareness among healthcare professionals and the public is crucial in identifying COPD at earlier stages, allowing for timely interventions and better management strategies. Consequently, there is a growing demand for improved diagnostic tools, more effective treatments, and increased research efforts aimed at understanding and combating COPD. This evolving landscape underscores the importance of education and proactive healthcare initiatives to mitigate the impact of COPD on individuals and healthcare systems, this is bolstering the growth of the market.

The rise in COPD cases globally presents a significant public health challenge, driven in part by factors such as tobacco smoking, which remains a leading risk factor for the disease. The increasing prevalence of adult smoking worldwide has contributed to a higher burden of COPD, highlighting the urgent need for comprehensive smoking cessation programs and stricter tobacco control measures. Additionally, occupational exposures to pollutants and indoor air pollution further exacerbate the risk of developing COPD. Addressing these environmental factors through regulatory policies and workplace interventions is crucial in reducing the incidence and progression of COPD, thereby improving the quality of life for affected individuals and lessening the strain on healthcare resources.

Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, Sanofi and Regeneron Pharmaceuticals are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.

Will Rising Side Effects of Drugs Used in Treating Chronic Obstructive Pulmonary Disease (COPD) Restrain Its Application?

The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.

Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.

The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.

Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.

Category-Wise Acumens

Which Factors Contribute to the Dominance of Drugs Segment in Chronic Obstructive Pulmonary Disease Market?

The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.

Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.

Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.

The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.

Which Factors Enhance the Use of Chronic Obstructive Pulmonary Disease in Hospitals?

Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.

Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.

Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.

Country/Region-wise Acumens

Will Rising Prevalence of COPD in North America Mature Chronic Obstructive Pulmonary Disease Market?

North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market's size and growth.

North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region's strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.

Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America's position as a leader in the global COPD market.

Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.

Will Increasing Air Pollution in Asia Pacific Drive the Growth of Chronic Obstructive Pulmonary Disease Market?

The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.

A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.

Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.

Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.

Competitive Landscape

The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include:

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline (GSK)

Novartis

Merck & Co.

Pfizer

Teva Pharmaceuticals

Sanofi

Mylan

Chiesi Farmaceutici

Sunovion Pharmaceuticals

Orion Corporation

Cipla

Reddy's Laboratories

Vectura Group

Circassia Pharmaceuticals

Theravance Biopharma

Verona Pharma

Glenmark Pharmaceuticals

Pulmatrix

Latest Developments

In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.

In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).

Chronic Obstructive Pulmonary Disease Market, By Category

• Type:
• Chronic Bronchitis
• Emphysema
• Treatment Type:
• Drugs
• Bronchodilator Monotherapy
• Short-Acting Beta2-Agonists (SABAS)
• Long-Acting Beta2-Agonists (LABAS)
• Anti-Cholinergic Agents
• Anti-Inflammatory Drugs
• Oral And Inhaled Corticosteroids
• Anti-Leukotrienes
• Surgery
• Lung Volume Reduction Surgery (LVRS)
• Lung Transplant, Bullectomy
• Others
• Oxygen Therapy
• End-User:
• Hospitals
• Homecare Settings
• Clinics
• Others
• Region:
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Chronic Obstructive Pulmonary Disease Market, By Type

• Chronic Bronchitis
• Emphysema

5. Chronic Obstructive Pulmonary Disease Market, By Treatment Type

• Drugs
• Bronchodilator Monotherapy
• Short-Acting Beta2-Agonists (SABAS)
• Long-Acting Beta2-Agonists (LABAS)
• Anti-Cholinergic Agents
• Anti-Inflammatory Drugs
• Oral And Inhaled Corticosteroids
• Anti-Leukotrienes
• Surgery
• Lung Volume Reduction Surgery (LVRS)
• Lung Transplant, Bullectomy
• Others
• Oxygen Therapy

6. Chronic Obstructive Pulmonary Disease Market, By End User

• Hospitals
• Homecare Settings
• Clinics
• Others

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• AstraZeneca
• Boehringer Ingelheim
• GlaxoSmithKline (GSK)
• Novartis
• Merck & Co.
• Pfizer
• Teva Pharmaceuticals
• Sanofi
• Mylan
• Chiesi Farmaceutici
• Sunovion Pharmaceuticals
• Orion Corporation
• Cipla
• Reddy's Laboratories
• Vectura Group
• Circassia Pharmaceuticals
• Theravance Biopharma
• Verona Pharma
• Glenmark Pharmaceuticals
• Pulmatrix

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References